Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy

Chaumard, Natacha; Limat, Samuel; Villanueva, Cristian; Nerich, Virginie; Fagnoni, Philippe; Bazán, Fernando; Chaigneau, L.; Dobi, Erion; Cals, L.; Pivot, Xavier

doi:10.1016/j.breast.2011.10.009

Cited by 26 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For obese women, impaired clearance and greater body exposure to chemotherapy agents have been documented, including use of doxorubicin, cyclophosphamide, and fluorouracil . For the populations of this study, univariate analysis showed BMI correlated with neutropenia, but it did not predict side effects in our multivariate regression analyses as other studies . Nevertheless, it seems to be consistent with a systematic review that fewer neutropenic events was seen in obese women .…”

Section: Discussionsupporting

confidence: 86%

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

Chow

Biganzoli

Leo

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

Chow

Biganzoli

Leo

et al. 2017

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…The rates became very close when they compared patients aged ≤ 50 (65.8% anemic) with the ones aged > 50 (62.3% anemic) (19).…”

Section: Discussionmentioning

confidence: 87%

“…Contrary to our results, Chaumard et al found a significant difference regarding the prevalence of anemia between the patients with BMI ≤ 25 and those with BMI > 25 (P = 0.02). Anemia was less frequent among their overweight and obese subjects (57.6%), compared with subjects with BMI ≤ 25 (69.6%) (19).…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, Goldrick et al found the highest rate of anemia in patients taking "cyclophosphamide + epirubicin + 5-fluorouracil" regimen (98.2%) while anemia rate in patients taking "doxorubicin + cyclophosphamide followed by paclitaxel or docetaxel" regimen was third highest (81.8%) (2). In addition, Chaumard et al found the highest prevalence of anemia (92.3%) among patients taking concomitant taxanes regimen (19).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

et al. 2016

View full text Add to dashboard Cite

Background: Breast cancer is the second most common malignancy in women, worldwide. Several etiologic factors may cause anemia in a patient with breast cancer. Anemia is a prevalent complication in patients with breast cancer who undergo chemotherapy which affects the health status and quality of life in these patients. The aim of this study was to evaluate the prevalence of anemia in patients with non-metastatic breast cancer who underwent adjuvant chemotherapy. Methods: In this cross-sectional study, 144 women with non-metastatic breast cancer who referred to radiotherapy and oncology department of Imam Reza hospital and met inclusion criteria were included. Data were obtained from patients' archived documents and were analyzed by SPSS software (version16). Results: In this study, 41% of patients were anemic before the chemotherapy and 43.1% of patients became anemic during and after treatment. The prevalence of post-chemotherapy anemia was significantly higher in advanced stages of cancer (P = 0.01). The chance of developing anemia were more in patients who underwent 8 cycles and AC + paclitaxel regimen, compared to the ones with 6 cycles and other regimens. There was no significant relationship between the prevalence of anemia and type of chemotherapy regimen, number of chemotherapy cycles, positive lymph nodes, co-morbidities, menstrual status, and body mass index (BMI). Conclusions: Due to the high prevalence of chemotherapy-induced anemia and its effects on quality of life, even mild degrees of anemia should be detected and evaluated before treatment. Considering early interventions is of cardinal importance, especially in the elderly.

show abstract

“…In the University Hospital of Besançon, the 3 prospective clinical studies enrolled 277 patients between June 2003 and November 2011 [14][15][16] with the Sequence, Satin, and Erycost trials including 124, 41, and 112 patients, respectively. Of those patients, 100 cases were eligible in the present prospectiveretrospective analysis.…”

Section: Patients and Patient Characteristicsmentioning

confidence: 99%

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

et al. 2015

View full text Add to dashboard Cite

Background. The Oncotype DX recurrence score (RS) assay has been validated for prediction of 10-year risk of distant recurrence and likelihood of benefit from chemotherapy in patients with estrogen receptor (ER)-positive, HER2-negative early breastcancer. Patients with high RS tumors have substantial benefit, and patients with low RS tumors have minimal if any benefit from chemotherapy. Tumor size is used as a key parameter when selecting patients for neoadjuvant chemotherapy. The aim of this study was to assess the distribution of RS in patients selected for neoadjuvant chemotherapy primarily according to tumor size. Patients and Methods. Patients with ER-positive and HER2-negative tumors that were node-negative or had no more than 1 positive node from three trials were included in this study. Oncotype DX was performed at Genomic Health, Inc., blinded

show abstract

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy

Abstract: Taking into account the following factors: type of chemotherapy, BMI, age, Hb at baseline should allow a better identification of patients at risk of anemia.

Cited by 26 publications

References 28 publications

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Contact Info

Product

Resources

About